Innovative Technology Ossianix specializes in developing shark-derived VNAR antibodies capable of penetrating challenging biological barriers such as the blood-brain barrier, opening opportunities for delivering therapeutics to hard-to-reach brain targets and neurodegenerative conditions.

Strategic Collaborations Recent partnerships with industry leaders like Novo Nordisk and collaborations within the UK Science Park demonstrate Ossianix’s active engagement in advancing BBB-crossing therapeutics, positioning it as a key player for companies seeking innovative delivery platforms.

Market Focus Areas With current programs targeting neurodegeneration, neurooncology, ALS, pain, and botulism, there is a strong opportunity to approach biotech and pharma firms focused on neurological and metabolic disease treatments.

Funding & Revenue Although precise funding figures are not available, the company's revenue range of 1-10 million USD indicates a growing biotech enterprise, suggesting potential for investment or acquisition prospects for companies interested in innovative biologics.

Global Presence Ossianix's dual locations in the US and UK facilitate access to international markets, collaborative research networks, and the potential to expand partnerships with European and North American pharmaceutical firms seeking advanced biologic delivery technologies.